Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

Oncotarget - 26 Apr 2016

Patani Harshnira, Bunney Tom D, Thiyagarajan Nethaji, Norman Richard A, Ogg Derek, Breed Jason, Ashford Paul, Potterton Andrew, Edwards Mina, Williams Sarah V, Thomson Gary S, Pang Camilla S M, Knowles Margaret A, Breeze Alexander L, Orengo Christine, Phillips Chris, Katan Matilda

Abstract excerpt

Frequent genetic alterations discovered in FGFRs and evidence implicating some as drivers in diverse tumors has been accompanied by rapid progress in targeting FGFRs for anticancer treatments. Wider assessment of the impact of genetic changes on the activation state and drug responses is needed to better link the genomic data and treatment options. We here apply a direct comparative and comprehensive analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to NIH 3T3 Cells

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 26992226
DOI: 10.18632/oncotarget.8132
PMCID: PMC5029699

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.PMID 26992226Read ↗

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Semantic proximity Read ↗

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types.Semantic proximity Read ↗

Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Semantic proximity Read ↗

FGFR rearrangements: oncogenic drivers and therapeutic targets.Semantic proximity Read ↗

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.Semantic proximity Read ↗

Landscape of drug-resistance mutations in kinase regulatory hotspotsSemantic proximity Read ↗

Cross-gene kinase domain hotspot analysis with AI pathogenicity prediction identifies FGFR2 D650G as a candidate actionable variantSemantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Semantic proximity Read ↗

The D647N mutation of FGFR1 induces ligand-independent receptor activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.